We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Troponin I Levels Predict Coronary Artery Disease Severity

By LabMedica International staff writers
Posted on 20 Mar 2018
Although coronary artery disease (CAD) may be present early in life, its progression over time is highly unpredictable. More...
Coronary atherosclerosis can progress at variable rates, ranging from a gradual increase in luminal narrowing to an abrupt progression to total luminal occlusion.

Total luminal occlusion is often a result of disruption of a vulnerable non-stenotic plaque attributable to rupture or erosion and subsequent thrombosis. Consequently, CAD progression may be silent and gradual or sudden and catastrophic, leading to acute coronary syndrome or death.

Medical scientists at Emory University School of Medicine (Atlanta, GA, USA) studied 3,087 patients (aged 63±12 years, 64% men) undergoing cardiac catheterization without evidence of acute myocardial infarction, the severity of CAD was calculated by the number of major coronary arteries with ≥50% stenosis and the Gensini score. CAD progression was assessed in a subset of 717 patients who had undergone ≥2 coronary angiograms more than three months before enrollment.

Fasting arterial blood samples were collected at cardiac catheterization and stored at −80 °C. High‐sensitivity troponin I (hsTnI) was measured using the Abbott ARCHITECT analyzer, which has a limit of detection of 1.2 pg/mL and an interassay coefficient of variation of <10% at 4.7 pg/mL. Serum high‐sensitivity C‐reactive protein (hs‐CRP) levels were determined in 2,127 patients using a particle‐enhanced immunoturbidimetric assay that has a lower limit of detection of 0.03 mg/L.

The scientists reported that high‐sensitivity troponin I (hsTnI) levels were detected in almost all patients (99.9%) and were lowest in subjects without significant native CAD (median, 3.3 pg/mL; interquartile range [IQR], 2.2–6 pg/mL) compared with those with 1‐vessel CAD (median, 4.3 pg/mL; IQR, 2.7–7.7 pg/mL), 2‐vessel CAD (median, 5.1 pg/mL; IQR, 3–8.6 pg/mL), or 3‐vessel CAD (median, 5.7 pg/mL; IQR, 3.4–9.8 pg/mL). The hsTnI level was also a significant predictor of incident death, cardiovascular death, myocardial infarction, revascularization, and cardiac hospitalizations, independent of the covariates and CAD severity.

The authors concluded that an elevated hsTnI level is closely associated with more severe CAD, with its accelerated progression, and with incident adverse cardiovascular events, independent of other clinical risk factors and hs‐CRP levels. This study provides additional support for the potential role of hsTnI as a marker of the presence, progression, and outcomes in CAD. The study was published on March 6, 2018, in the Journal of the American Heart Association.

Related Links:
Emory University School of Medicine


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Pan-Cancer Panel
TruSight Oncology 500
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.